Portfolio Lab

Alumis Inc.

  • Stock
  • Ticker ALMS
  • Nasdaq

Health care · Pharmaceuticals · USA

$3.96 −8.55%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Alumis Inc. since 06/2024, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

ALMSGlobal equities (VT)

$10,000 grew to $8,337. Global equities (VT): $10,273.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −86.9% in 11/2026, measured from the peak in 07/2026. The old peak has not been reached again yet.

1-year return
−42.8%
Return p.a. since 06/2024
−39.7%
Volatility p.a.
136.2%
Largest decline
−86.9%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue–172.72.11.91.71.71.9
Operating income-99-102-141-115-96-98-149-99
EBITDA-98-101-140-114-96-98-148-98
Net income-95-9959-111-93-93-142-95
Earnings per share-0.23-1.820.77-1.06-0.94-0.74-1.11-0.73
Balance sheet
Total assets341261611488412672561489
Liabilities8193126103111105108110
Equity260168485385301567452378
Cash1701291526590646458
Cash flow
Operating cash flow-75-80-106-111-72-87-82-80
Capital expenditure-0.40.0-0.60.00.0-0.2-0.2-0.5
Free cash flow-75-80-107-111-72-87-82-80

Value it:DCF calculatorMultiples calculator

Annual returns

* partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
12 Nov 2026−$0.73
13 Aug 2026−$1.11
14 May 2026−$0.74
19 Mar 2026−$0.94
13 Nov 2025−$1.06
13 Aug 2025$0.77
14 May 2025−$1.82
19 Mar 2025−$0.23
13 Nov 2024−$1.73
13 Aug 2024–

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€464m
Market cap in trading currency
$512m
Enterprise value
$454m
P/E
–
P/S
70.73
P/B
1.35
EV/Sales
62.76
EV/EBITDA
–
Earnings yield
–
FCF yield
-62.7%

Results (last four quarters)

Revenue
$7.24m
Gross profit
–
EBITDA
−$439m
Net income
−$423m
Earnings per share
−$3.52
Revenue per share
$0.06
Revenue growth
−7.7%
Earnings growth
–

Profitability

Gross margin
–
Operating margin
-6,116.7%
Net margin
-5,844.5%
Return on equity
-110.9%
Return on assets
-86.6%

Balance sheet and cash flow

Cash
$57.7m
Cash per share
$0.45
Financial debt
–
Debt/equity %
–
Current ratio
5.57
Book value per share
$2.93
Operating cash flow
−$320m
Free cash flow
−$321m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
–

Shares and trading

Shares outstanding
129m
Volume
1.79m
Avg. volume 3 months
2.82m
Relative volume
0.6

Price and technicals

Price
$3.96
1 day
−8.5%
52-week high
$30.30
52-week low
$3.96
Distance to 52-week high
−86.9%
Distance to 52-week low
0.0%
Distance to 50-day line
−40.8%
Distance to 200-day line
−80.1%
RSI (14)
23
Volatility 1M
89.0%

Performance

1 week
−29.3%
1 month
−41.9%
3 months
−82.8%
6 months
−82.0%
YTD
−59.4%
1 year
−39.7%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has ALMS performed since 06/2024?

$10,000 grew to $2,977 by 20 Nov 2026, which is −39.7% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is ALMS?

Volatility was 136.2% per year, measured on monthly returns. The largest decline from a peak was −86.9%, with the low in 11/2026.

How does ALMS compare with a broad equity ETF?

Over the same period Global equities (VT) returned +12.0% per year at 12.5% volatility, ALMS returned −39.7% at 136.2%. The correlation of monthly returns was 0.19; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Alumis Inc. (ALMS): Return and risk | Portfolio Lab